Growth Metrics

Omeros (OMER) Total Non-Current Liabilities (2021 - 2026)

Omeros recorded quarterly Total Non-Current Liabilities of $265.5 million in Q1 2026, down 39.82% quarter-over-quarter from $441.2 million in Q4 2025, and down 40.24% year-over-year from $444.2 million in Q1 2025.

Omeros' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $265.5 million for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities fell 40.24% year-over-year to $265.5 million; the TTM figure through Mar 2026 stood at $265.5 million (down 40.24% YoY), while the FY2025 annual figure was $441.2 million, down 3.08% from the prior year.
  • Total Non-Current Liabilities came in at $265.5 million for Q1 2026 at Omeros, down from $441.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $507.0 million in Q3 2023 to a low of $251.2 million in Q2 2025.
  • A 5-year average of $425.8 million and a median of $455.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities jumped 35.22% in 2023 and sank 47.54% in 2025, its largest moves.
  • Omeros' Total Non-Current Liabilities stood at $504.8 million in 2022, then slipped by 20.54% to $401.2 million in 2023, then advanced by 13.47% to $455.2 million in 2024, then fell by 3.08% to $441.2 million in 2025, then tumbled by 39.82% to $265.5 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $265.5 million, $441.2 million, and $253.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 11.03 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 42,980.09
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 95.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 110.28 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.87 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 7.32 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 4.05 Bn
10 Omeros 772.03 Mn 636.71 Mn 9.31 Mn 265.48 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 265.48 Mn
Dec 31, 2025 441.16 Mn
Sep 30, 2025 253.66 Mn
Jun 30, 2025 251.17 Mn
Mar 31, 2025 444.21 Mn
Dec 31, 2024 455.19 Mn
Sep 30, 2024 464.41 Mn
Jun 30, 2024 478.82 Mn
Mar 31, 2024 506.73 Mn
Dec 31, 2023 401.16 Mn
Sep 30, 2023 507.02 Mn
Jun 30, 2023 506.42 Mn
Mar 31, 2023 504.74 Mn
Dec 31, 2022 504.84 Mn
Sep 30, 2022 502.87 Mn
Jun 30, 2022 377.38 Mn
Mar 31, 2022 373.27 Mn
Dec 31, 2021 394.37 Mn